ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION Drug Patent Profile

What is the product’s revenue model and where does it sit in the allergy-care stack?

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is an OTC, fixed-dose combination allergy product built around fexofenadine plus pseudoephedrine (extended-release). The commercial engine for this class is not prescription volume; it is seasonal retail turnover, pharmacy counter conversion, and promotional pricing tied to cold-and-allergy cycles.

Core demand drivers

• Seasonality and weather: Allergy incidence increases in peak pollen and seasonal respiratory periods; demand typically spikes in spring and fall.
• Cold and allergy overlap: Pseudoephedrine-based congestion relief captures patients treating “allergies plus stuffy nose” rather than antihistamine-only use.
• OTC switching dynamics: Consumers move between equivalent OTC congestion-antihistamine combinations based on perceived speed of relief, brand trust, and price.

Place in the portfolio

• Fexofenadine-based OTC products sit in the “second-generation antihistamine” lane versus older sedating antihistamines.
• The “-D” pseudoephedrine combination segment is structurally different from non-decongestant antihistamines due to additional regulatory controls and patient handling at point of sale.

How does regulation shape availability, pricing power, and sell-through?

Pseudoephedrine products face controlled distribution requirements in the US, which affects retail execution and purchasing friction.

Regulatory and retail implications for pseudoephedrine combos

• Retailers apply ID checks and transaction limits (framework under US federal methamphetamine precursor controls).
• Availability can be constrained by store-level compliance practices and inventory handling.
• Market shares tilt toward brands with strong distribution relationships and retailer familiarity.

Business impact on financial trajectory

• Pricing power is less about pure clinical differentiation and more about execution reliability: consistent inventory, compliant stocking, and fast replenishment during peak seasons.
• Promotion cycles (coupons, multi-buy offers, and end-cap placements) matter more than long-term brand equity in OTC congestion segments.

What market dynamics influence growth or decline over a 2- to 5-year horizon?

The market for OTC allergy and congestion products has recurring forces that move unit volume and net sales.

Supply and competitive pressure

• Multiple OTC combinations exist across categories:
  • Second-generation antihistamine alone (non-decongestant)
  • Second-generation antihistamine plus different decongestants
  • Non-antihistamine congestion-only products
• Competition intensifies when retailers expand private label or when large brands run aggressive seasonal promotions.

Consumer substitution

• When prices rise, consumers typically trade down to lower-cost equivalents within congestion-antihistamine or congestion-only categories.
• When perceived relief is weak or product “feel” (onset, congestion impact) is inconsistent, churn increases.

Seasonal promotional behavior

• The segment is promo-heavy: price and retailer placement drive category conversion during peak allergy months.
• Net sales can grow even with flat underlying unit growth if mix shifts toward higher-priced formats or if promotional intensity moderates.

How does ALLEGRA-D’s lifecycle typically behave for an OTC combination product?

For an established OTC combination brand, the financial path usually follows a pattern:

• Early stage: share capture from prior congestion-allergy standards, fast retailer adoption.
• Mature stage: share stability with incremental gains through seasonal promotion and packaging variants.
• Later maturity: flat-to-declining units if category headwinds increase (private label, stronger competitors, weaker seasonal peaks), with net sales supported by price/mix and reduced promotional depth.

For ALLEGRA-D specifically, the stable part of the model is that:

• congestion plus allergy symptom treatment is persistent unmet convenience demand,
• second-generation antihistamine positioning stays durable versus older sedating alternatives,
• pseudoephedrine combo use keeps a distinct user set that does not fully substitute into antihistamine-only products.

What are the key financial levers that determine net sales and gross margin?

Because this is an OTC branded combo, net sales and gross margin move through a smaller set of levers than prescription launches.

Net sales levers

• Seasonal unit volume in peak months.
• Price per unit (MSRP and realized pricing after retailer discounts and promotions).
• Channel mix (mass, club, grocery, pharmacy).
• Package economics (store brand or competitor pack sizes influence shelf price comparisons).

Gross margin levers

• Manufacturing scale and sourcing for active ingredients and extended-release formulation.
• Trade spend (co-op advertising, retailer allowances, slotting during peak seasons).
• Promotional intensity (depth and duration of seasonal discounts).

Profit sensitivity

• In OTC, promotional depth can move earnings quickly: the segment is competitive, and demand is seasonal but price-sensitive.

Where are the patent and exclusivity edges that can influence longer-run revenue?

Long-run trajectory for OTC drugs usually depends on:

• the status of active ingredient patents and formulation/exclusivity that can constrain generic or authorized generic entry,
• the status of combination intellectual property (fixed-dose plus extended-release),
• the presence and timing of generic competition that compresses price and margins.

For ALLEGRA-D 24 HOUR, market outcomes hinge on when competitors can legally sell equivalent formulations and how aggressively retailers stock them. However, without a verified, up-to-date exclusivity and patent status dataset for the exact combination and dosage form, a complete and precise financial forecast (including post-expiration share loss curves) cannot be constructed.

What market share and price dynamics typically happen in OTC antihistamine-decongestant combos once generics arrive?

When generic equivalents enter for established OTC combo brands, financial trajectory generally shifts to:

• downward pressure on net price as retailers widen shelf access for lower-cost equivalents,
• trade spend increase as the branded firm defends shelf position,
• mix shift toward larger packs or promoted SKUs that maintain absolute dollar sales,
• unit volatility tied to promotion cadence and seasonal peaks.

For an established brand like ALLEGRA-D, the brand typically retains some share through:

• consumer brand preference,
• retailer shelf allocation favoring known movers,
• perceived efficacy and tolerability positioning.

But the magnitude of erosion depends on the exact strength of combination/formulation protection and the speed and coverage of generic entrants.

Financial trajectory summary: what a realistic baseline path looks like

Given OTC realities, ALLEGRA-D 24 HOUR’s financial trajectory typically reflects three drivers:

1. Seasonality governs topline spikes
2. Retail pricing and promotional depth governs realized net
3. Generic/authorized generic penetration governs longer-run margin compression

A plausible directional read for established OTC combination brands is:

• Short run (season-to-season): net sales oscillate with pollen/cold cycles and promotional intensity; margins swing with discount depth.
• Medium run (multi-year): absent a material protection expiry or competitor shock, the baseline is stable brand share with periodic promotional optimization.
• Long run (post-meaningful competition entry): net sales growth slows or declines while gross margin compresses.

A precise numeric forecast requires verified proprietary and regulatory market data. This analysis is limited to structural dynamics and commercial mechanics.

Key Takeaways

• ALLEGRA-D 24 HOUR’s market is driven by seasonal retail turnover and OTC point-of-sale execution rather than prescription demand.
• The pseudoephedrine component creates distribution and compliance friction, which can favor brands with reliable retail handling and shelf continuity.
• Financial outcomes track three variables: seasonal units, realized net price after promotion, and competitive/generic penetration over time.
• Over a multi-year horizon, the segment’s economics tend to move from brand-defense pricing toward promotional trade-offs once equivalent competition widens.

FAQs

1. Is ALLEGRA-D 24 HOUR a prescription or OTC product?
   It is an OTC product sold through retail channels.

2. What symptom set does ALLEGRA-D 24 HOUR target?
   Allergy symptoms plus nasal congestion, using a combination of an antihistamine and a decongestant.

3. What most influences quarterly performance for OTC allergy-decongestant brands?
   Seasonality and the depth/timing of retail promotions.

4. Why does pseudoephedrine affect the business model beyond clinical efficacy?
   It changes retailer purchasing friction through controlled-distribution compliance, which affects availability and execution.

5. What is the main long-run threat to branded OTC combo revenue?
   Increased competitive coverage from equivalent products, including generic penetration that compresses net price and margins.

References

[1] U.S. Food and Drug Administration. Pseudoephedrine and Ephedrine Products Regulation (Methamphetamine Precursor Controls). FDA website.
[2] U.S. Drug Enforcement Administration. Combat Methamphetamine Epidemic Act (CMEA) and precursor control requirements for pseudoephedrine-containing products. DEA website.
[3] FDA. OTC Drug Product Safety and Effectiveness Reviews and Related Guidance (OTC overview). FDA website.